This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epigenomics Valuation

Is ECX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ECX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ECX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ECX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ECX?

Key metric: As ECX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ECX. This is calculated by dividing ECX's market cap by their current revenue.
What is ECX's PS Ratio?
PS Ratio	1.8x
Sales	€339.23k
Market Cap	€616.00k

ECX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	30.7x
Enterprise Value/EBITDA	-2.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ECX's PS Ratio compare to its peers?

The above table shows the PS ratio for ECX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
SBH Sangui Biotech International	3.8x	n/a	€419.8k
PA8K Paion	0.003x	n/a	€42.8k
PA8 Paion	0.2x	30.2%	€2.6m
ECX Epigenomics	1.8x	n/a	€616.0k

Price-To-Sales vs Peers: ECX is expensive based on its Price-To-Sales Ratio (1.8x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does ECX's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ECX is good value based on its Price-To-Sales Ratio (1.8x) compared to the European Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is ECX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ECX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ECX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.74

1.9%

-7.4%

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

6.7%

3.9%